The BioMedWire Podcast

The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit.

To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.

“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”

Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit.

To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.

“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”

Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.

To begin the interview, Climaco discussed CNS Pharmaceuticals’ business model, including the company’s recent announcement of an exclusive in-license agreement to expand its development pipeline.

“We are an oncology drug development company. Specifically, our space is neuro-oncology – cancers of the brain and the central nervous system. Traditionally, these are some of the most difficult and deadly cancers,” he said. “They are very challenging to treat, because they lie beyond the blood-brain barrier, which is this very specialized network of cells that protects the most important organ in the body. It's very hard to get drugs and treatments to the brain when you have tumors growing in it, so that is really what we specialize in.”

“We have a very exciting compound called Berubicin. It's a first-in-class drug that penetrates the blood-brain barrier and treats brain cancer. This is in a late stage, designed to be pivotal trial, with over 250 patients in the United States and Europe currently enrolled. It'll be reading top-line data in the first half of next year, so we're very excited about that. We've been working on Berubicin since the company's inception back in 2017.”

“Our recent news is equally exciting. After many years of searching and diligence and evaluating over 200 different compounds for potential in-license, we settled on an amazing drug called TPI-287, which is a novel abeotaxane of the taxane family. This is also a unique blood-brain barrier penetrant drug that was specifically designed to treat these very difficult brain cancers, such as glioblastoma. This drug has already been used in 350 patients in a series of phase one studies. We are just getting started on planning what will be another designed to be pivotal study for this very exciting drug.”

Join IBN’s Carmel Fisher and John Climaco, CEO of CNS Pharmaceuticals Inc., to learn more about what sets Berubicin, as well as the company’s new TPI-287 candidate, apart from anything else in development for glioblastoma.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.

To begin the interview, Climaco discussed CNS Pharmaceuticals’ business model, including the company’s recent announcement of an exclusive in-license agreement to expand its development pipeline.

“We are an oncology drug development company. Specifically, our space is neuro-oncology – cancers of the brain and the central nervous system. Traditionally, these are some of the most difficult and deadly cancers,” he said. “They are very challenging to treat, because they lie beyond the blood-brain barrier, which is this very specialized network of cells that protects the most important organ in the body. It's very hard to get drugs and treatments to the brain when you have tumors growing in it, so that is really what we specialize in.”

“We have a very exciting compound called Berubicin. It's a first-in-class drug that penetrates the blood-brain barrier and treats brain cancer. This is in a late stage, designed to be pivotal trial, with over 250 patients in the United States and Europe currently enrolled. It'll be reading top-line data in the first half of next year, so we're very excited about that. We've been working on Berubicin since the company's inception back in 2017.”

“Our recent news is equally exciting. After many years of searching and diligence and evaluating over 200 different compounds for potential in-license, we settled on an amazing drug called TPI-287, which is a novel abeotaxane of the taxane family. This is also a unique blood-brain barrier penetrant drug that was specifically designed to treat these very difficult brain cancers, such as glioblastoma. This drug has already been used in 350 patients in a series of phase one studies. We are just getting started on planning what will be another designed to be pivotal study for this very exciting drug.”

Join IBN’s Carmel Fisher and John Climaco, CEO of CNS Pharmaceuticals Inc., to learn more about what sets Berubicin, as well as the company’s new TPI-287 candidate, apart from anything else in development for glioblastoma.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

The latest episode features Rob Etherington, President and CEO of Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.

To begin the interview, Etherington discussed Clene’s mission, including its novel approach to the treatment of diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

“Clene Inc. is focused entirely on improving mitochondrial health and protecting neuron function. This is a very important thing we can do to treat neurodegenerative diseases such as ALS, MS and Parkinson's,” he said. “This is particularly topical today, because the World Health Organization is predicting that neurodegenerative diseases will become the second-most prevalent cause of death within the next two decades. We're pioneering a very unique approach: the use of an oral suspension that patients can drink to treat the deficits that they might have if afflicted with one of these devastating neurodegenerative diseases.”

The latest episode features Rob Etherington, President and CEO of Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.

To begin the interview, Etherington discussed Clene’s mission, including its novel approach to the treatment of diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

“Clene Inc. is focused entirely on improving mitochondrial health and protecting neuron function. This is a very important thing we can do to treat neurodegenerative diseases such as ALS, MS and Parkinson's,” he said. “This is particularly topical today, because the World Health Organization is predicting that neurodegenerative diseases will become the second-most prevalent cause of death within the next two decades. We're pioneering a very unique approach: the use of an oral suspension that patients can drink to treat the deficits that they might have if afflicted with one of these devastating neurodegenerative diseases.”

The latest BioMedWire podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio’s recent Phase 2/3 Alzheimer’s study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio’s strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases.

“Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer’s research, underscores the importance of our work and the promise it holds for patients.”

Join IBN’s Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio’s recent achievements, the next steps for buntanetap, and the company’s future goals.

The latest BioMedWire podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio’s recent Phase 2/3 Alzheimer’s study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio’s strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases.

“Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer’s research, underscores the importance of our work and the promise it holds for patients.”

Join IBN’s Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio’s recent achievements, the next steps for buntanetap, and the company’s future goals.

The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit.

To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.

“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”

Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

Conservative alt-coin podcast hosts Drew Taylor and Brent Bates recently welcomed guests and the audience to another episode of their wildly popular Wild West Crypto Show. The program took a somber turn to delve into current events in Afghanistan and remember service members and people who’ve given their lives for this country. The hosts split segments normally reserved for guests to discuss how global events will affect the markets, as well as share their takes on some wild times. Bates’ Over the Fence Post segment showcased his personal riled-up experience to encourage others to attend city council meetings. Taylor’s Cowboy Logic segment highlighted the topic of responsibility and the reasons our president needs to step up and take his full share. In addition, the hosts provided their insight on the roots of the USA in a unique comparison to cryptos. “The interesting thing is . . . we were the first fully decentralized government in the world. Every government before the U.S. government was centralized. There was either a centralized theocracy, monarchy or a dictator . . . We were the first to come along . . . and had some very wise men who set up a decentralized country,” Bates said. “And, in fact, cryptocurrency is going back to the roots of being decentralized. . .”